Ocular Therapeutix Inc (NASDAQ:OCUL), an integrated biopharmaceutical company focused on retinal disease, said on Friday that it has granted inducement equity awards to nine newly hired non-executive employees.

The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Granted effective as of 14 September 2026, the inducement equity awards consist of non-statutory stock option awards to purchase up to an aggregate of 64,850 shares of Ocular's common stock and restricted stock unit awards representing the right to receive an aggregate of 21,350 shares of Ocular's common stock. The stock option awards have an exercise price of USD10.72 per share, equal to the closing price of Ocular's common stock on The Nasdaq Global Market on the effective date of grant. Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly instalments over the following three years, subject to the recipient's continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual instalments on the first, second and third anniversaries of the date of grant, subject to the recipient's continued service to Ocular through the applicable vesting dates.